Article

Dr. Kolodziej Addresses the Impact of Payer Policy on the Use of Immunotherapy

Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that in regard to payers impacting the use of immunotherapies, most payers have decided they will respect the judgment of the Food and Drug Administration, Centers for Medicare & Medicaid Services and the National Comprehensive Cancer Network.

Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that in regard to payers impacting the use of immunotherapies, most payers have decided they will respect the judgment of the Food and Drug Administration, Centers for Medicare & Medicaid Services and the National Comprehensive Cancer Network (NCCN). "If NCCN says the immunotherapies are worth doing we by and large pay for them," said Dr Kolodziej. He notes that due to the high cost of the therapies, they are still regulated. Dr Kolodziej says that the future is uncertain because there will be a shift of responsibility of cost to providers and possibly patients.

This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.

Related Videos
Drs Lillian L. Siu and Matthew G. Vander Heiden
Jaime Almandoz, MD, MBA
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Kimberly Westrich, MA, chief strategy officer, NPC
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo